Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024510
Abstract: Key Points • PV with or without rituximab was tested in relapsed/refractory CLL, including after progression during treatment with a covalent BTKi.• These fixed-duration treatments were safe and showed promising efficacy in both covalent BTK-naïve… read more here.
Keywords: relapsed refractory; without rituximab; refractory cll; fixed duration ... See more keywords